AU2005269733B2 - Induction of apoptosis in Toll-like receptor expressing tumor cells - Google Patents

Induction of apoptosis in Toll-like receptor expressing tumor cells Download PDF

Info

Publication number
AU2005269733B2
AU2005269733B2 AU2005269733A AU2005269733A AU2005269733B2 AU 2005269733 B2 AU2005269733 B2 AU 2005269733B2 AU 2005269733 A AU2005269733 A AU 2005269733A AU 2005269733 A AU2005269733 A AU 2005269733A AU 2005269733 B2 AU2005269733 B2 AU 2005269733B2
Authority
AU
Australia
Prior art keywords
cells
cell
poly
tlr
tlr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005269733A
Other languages
English (en)
Other versions
AU2005269733A1 (en
Inventor
Isabelle Coste-Invernizzi
Serge Lebecque
Toufic Renno
Marie-Clotilde Rissoan
Bruno Salaun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2005269733A1 publication Critical patent/AU2005269733A1/en
Application granted granted Critical
Publication of AU2005269733B2 publication Critical patent/AU2005269733B2/en
Priority to AU2008249173A priority Critical patent/AU2008249173A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005269733A 2004-07-20 2005-07-19 Induction of apoptosis in Toll-like receptor expressing tumor cells Ceased AU2005269733B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008249173A AU2008249173A1 (en) 2004-07-20 2008-11-24 Induction of apoptosis in toll-like receptor expressing tumor cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58961604P 2004-07-20 2004-07-20
US60/589,616 2004-07-20
PCT/US2005/025602 WO2006014653A1 (en) 2004-07-20 2005-07-19 Induction of apoptosis in toll-like receptor expressing tumor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008249173A Division AU2008249173A1 (en) 2004-07-20 2008-11-24 Induction of apoptosis in toll-like receptor expressing tumor cells

Publications (2)

Publication Number Publication Date
AU2005269733A1 AU2005269733A1 (en) 2006-02-09
AU2005269733B2 true AU2005269733B2 (en) 2008-10-30

Family

ID=35229744

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005269733A Ceased AU2005269733B2 (en) 2004-07-20 2005-07-19 Induction of apoptosis in Toll-like receptor expressing tumor cells
AU2008249173A Abandoned AU2008249173A1 (en) 2004-07-20 2008-11-24 Induction of apoptosis in toll-like receptor expressing tumor cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008249173A Abandoned AU2008249173A1 (en) 2004-07-20 2008-11-24 Induction of apoptosis in toll-like receptor expressing tumor cells

Country Status (12)

Country Link
US (2) US20060147456A1 (cg-RX-API-DMAC10.html)
EP (1) EP1768699A1 (cg-RX-API-DMAC10.html)
JP (1) JP2008507530A (cg-RX-API-DMAC10.html)
KR (1) KR20070043795A (cg-RX-API-DMAC10.html)
CN (1) CN101018567B (cg-RX-API-DMAC10.html)
AT (1) ATE511859T1 (cg-RX-API-DMAC10.html)
AU (2) AU2005269733B2 (cg-RX-API-DMAC10.html)
CA (1) CA2574176A1 (cg-RX-API-DMAC10.html)
MX (1) MX2007000770A (cg-RX-API-DMAC10.html)
NO (1) NO20070945L (cg-RX-API-DMAC10.html)
RU (1) RU2401661C9 (cg-RX-API-DMAC10.html)
WO (1) WO2006014653A1 (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20120189643A1 (en) * 2004-11-30 2012-07-26 Carton Jill M Toll Like Receptor 3 Antagonists, Methods and Uses
EP1993553B1 (en) 2006-03-02 2013-05-08 Agency for Science, Technology and Research Methods for cancer therapy and stem cell modulation
AU2007249698A1 (en) 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
JP5115921B2 (ja) * 2007-02-28 2013-01-09 株式会社ペルセウスプロテオミクス 腎癌の診断薬および治療薬
AU2008242540A1 (en) * 2007-04-24 2008-10-30 John Wayne Cancer Institute Functional toll-like receptors (TLR) on melanocytes and melanoma cells and uses thereof
JP2011504462A (ja) * 2007-11-02 2011-02-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍の予防および治療のための方法および化合物
WO2009073152A1 (en) * 2007-11-28 2009-06-11 Smart Tube, Inc. Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample
AU2009215795A1 (en) * 2008-02-21 2009-08-27 University Of Kentucky Research Foundation Ultra-small RNAs as toll-like receptor-3 antagonists
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
WO2010020590A1 (en) * 2008-08-20 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators
US8628762B2 (en) 2008-12-10 2014-01-14 Icahn School Of Medicine At Mount Sinai T-helper cell type 17 lineage-specific adjuvants, compositions and methods
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
KR101250419B1 (ko) * 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제
RU2014103159A (ru) * 2011-07-22 2015-08-27 Павел КАЛИНСКИЙ Опухолесективная модуляция хемокинов
CN102652802A (zh) * 2012-04-18 2012-09-05 南京中医药大学 癌毒方在制备调控肝癌细胞TLRs／NF-κB信号转导药物中的应用
EP2879669A4 (en) 2012-07-29 2016-04-13 Univ Colorado Regents ANTAGONISTS OF THE TOLL LIKE RECEPTOR 1/2 COMPLEX
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN105796594A (zh) * 2016-03-28 2016-07-27 南京大学 一种组合物在制备治疗肿瘤药物中的应用及该组合物的使用方法
CN106191238B (zh) * 2016-07-08 2020-01-10 中国医学科学院基础医学研究所 Tlr3预测肿瘤转移、评估预后和选择防治方案的应用
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN108295060A (zh) * 2018-04-08 2018-07-20 王长国 一种tlr7激动剂在增强cik细胞对肿瘤细胞杀伤力方面的应用
US11969402B2 (en) 2019-05-16 2024-04-30 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111117966A (zh) * 2020-03-02 2020-05-08 南通大学 一种利用乳酸的体外细胞培养方法
CN111579538B (zh) * 2020-04-22 2022-12-30 山东第一医科大学(山东省医学科学院) 一种利用凋亡试剂盒检测循环肿瘤细胞的方法
KR20220158640A (ko) * 2021-05-24 2022-12-01 주식회사 차백신연구소 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물
CN115820646A (zh) * 2022-12-20 2023-03-21 武汉光谷中源药业有限公司 一种增强免疫能力的免疫激动剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
WO2004050868A1 (ja) * 2002-11-29 2004-06-17 Japan Science And Technology Agency 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CN1040504A (zh) * 1988-06-22 1990-03-21 Hem研究公司 用双链核糖核酸调节淋巴激活素抗性细胞状态
RU2136278C1 (ru) * 1998-04-07 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Противоопухолевое средство
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
EP1412390A2 (en) * 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
WO2004050868A1 (ja) * 2002-11-29 2004-06-17 Japan Science And Technology Agency 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDRE, F et al. JOURNAL OF CLINICAL ONCOLOGY. Vol 22. No 4.,2004. pg 9619 *

Also Published As

Publication number Publication date
EP1768699A1 (en) 2007-04-04
CN101018567B (zh) 2011-07-27
AU2005269733A1 (en) 2006-02-09
US20090285779A1 (en) 2009-11-19
RU2401661C9 (ru) 2011-01-27
MX2007000770A (es) 2007-03-26
US20060147456A1 (en) 2006-07-06
JP2008507530A (ja) 2008-03-13
RU2007105987A (ru) 2008-08-27
RU2401661C2 (ru) 2010-10-20
CA2574176A1 (en) 2006-02-09
KR20070043795A (ko) 2007-04-25
CN101018567A (zh) 2007-08-15
NO20070945L (no) 2007-02-19
ATE511859T1 (de) 2011-06-15
WO2006014653A1 (en) 2006-02-09
AU2008249173A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
US20090285779A1 (en) Induction of apoptosis in toll-like receptor expressing tumor cells
US20240043541A1 (en) Methods for treating hematologic cancers
Beider et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
US12570710B2 (en) Targeting LILRB4 with CAR-T or CAR-NK cells in the treatment of cancer
US20240262909A1 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
US11081235B2 (en) Extracellular matrix metalloproteinase inducer (EMMPRIN) peptides and binding antibodies
Leiguarda et al. IMT504 provides analgesia by modulating cell infiltrate and inflammatory milieu in a chronic pain model
WO2011113041A2 (en) Neutralization of flt3 ligand as a leukemia therapy
US20160209425A1 (en) Use of dectin-1 activators for treatment of liver disorders
US10231952B2 (en) Use of arginine vasopressin receptor antagonists for the treatment of prostate cancer
JP5695905B2 (ja) Ｎｌｒｒ−１アンタゴニスト及びその使用
JP5665739B2 (ja) 炎症性疾患を治療するためのｃｄ９５インヒビターの使用
US20240391964A1 (en) Compositions and methods for the treatment of cancer
US20220363776A1 (en) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
JP2010540653A5 (cg-RX-API-DMAC10.html)
KR101781257B1 (ko) Rip3 발현촉진제를 유효성분으로 포함하는 항암보조용 조성물
US20210100859A1 (en) Herpes simplex virus (hsv) anticancer therapies
EP4034151A1 (en) Use of müllerian inhibiting substance inhibitors for treating cancer
Dalton et al. Bone Marrow Stroma Confers Resistance to
Renno TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired